| p38 mitogen-activated protein kinase inhibitor LY2228820 dimesylate | p38 MAPK inhibitor LY2228820 dimesylate |
| p53 DEN | Mutant p53 peptide pulsed dendritic cell vaccine |
| p53-SLP vaccine | p53 synthetic long peptide (70-251) vaccine |
| PA | Physician assistant |
| PABA | Para-aminobenzoic acid |
| PAC-1 | Procaspase activating compound-1 VO-100 |
| PAD | PAD regimen |
| PAH | Polycyclic aromatic hydrocarbon |
| PALA | Sparfosic acid |
| PANVAC-V | Inalimarev; Recombinant vaccinia-CEA-MUC-1-TRICOM vaccine |
| PAP | Prostatic acid phosphatase |
| Pap-H | Papaverine hydrochloride |
| PAR-101 | Tiacumicin B |
| PARP | Poly (ADP-ribose) polymerase |
| PARP-1 | Poly (ADP-ribose) polymerase-1 |
| PARPi-FL | Boron-dipyrromethene-modified olaparib fluorescent imaging agent |
| PBSCT | Peripheral blood stem cell transplant; Peripheral stem cell support |
| Pc 4 | Silicon phthalocyanine 4 |
| PCA | Patient-controlled analgesia |
| PCB | Polychlorinated biphenyl; Procarbazine hydrochloride |
| PCNSL | Primary central nervous system lymphoma; Primary CNS lymphoma |
| PCOS | Polycystic ovary syndrome |
| PCP | Primary care provider |
| PCR | Polymerase chain reaction |
| PCT | Porphyria cutanea tarda |
| PCV | PCV regimen |
| PCV 13 | Pneumococcal 13-valent conjugate vaccine |
| PCV7 | Pneumococcal 7-valent conjugate vaccine |
| Pd 103 | Palladium Pd-103 |
| PDAC | Pancreatic ductal adenocarcinoma |
| pDC vaccine | Plasmacytoid dendritic cell vaccine |
| PDGF | Platelet-derived growth factor |
| PDQ | Physician Data Query |
| PDX | Patient-derived xenograft |
| PEA | Palmidrol |
| PEB | BEP regimen; PEB regimen |
| PEComa | Perivascular epithelioid cell tumor |
| PEG | Polyethylene glycol |
| PEG 1000 cetyl ether cream | Polyethylene glycol 1000 cetyl ether cream |
| PEG-ASP | Pegaspargase |
| PEG-CSF MAXY-G34 | Pegylated granulocyte colony stimulating factor MAXY-G34 |
| PEG-IFN-a | Pegylated interferon alfa |
| PEG-IFN-a 2b | Peginterferon alfa-2b |
| PEG-IFNA2a | Peginterferon alfa-2a |
| PEG-IL-2 | PEG-interleukin-2 |
| PEG-irinotecan | Etirinotecan pegol |
| PEG-MGDF | Polyethylene glycosylated recombinant human megakaryocyte growth and development factor |
| PEGPH20 | Pegylated recombinant human hyaluronidase PH20 |
| PEG-rhMGDF | Polyethylene glycosylated recombinant human megakaryocyte growth and development factor |
| PEG-rHuIL-10 AM0010 | Pegilodecakin |
| PEG-SN38 | polyethyleneglycol-7-ethyl-10-hydroxycamptothecin |
| PEI | Alcohol ablation; Ethanol ablation; Percutaneous ethanol injection |
| PEITC | Phenethyl isothiocyanate |
| PEN | Penclomedine |
| PEP | Peplomycin |
| PEP02 | Irinotecan sucrosofate; Onivyde |
| PEP-3-KLH | PEP-3-KLH conjugate vaccine |
| PF-00299804 | Dacomitinib; Vizimpro |
| PF-3512676 | ProMune |
| PFIC | Progressive familial intrahepatic cholestasis |
| PFOB | Perflubron |
| PFP | Perflutren |
| PFS | Progression-free survival |
| PFT | Lung function test; Pulmonary function test |
| PG | Prostaglandin |
| PG-CPT | Polyglutamate camptothecin |
| PGE1 | Alprostadil; Prostaglandin E1 |
| P(GFLG)-ADR | doxorubicin-HPMA conjugate |
| PGJ | Purple grape juice |
| PG-TXL | Paclitaxel poliglumex |
| P-HA | Paclitaxel and hyaluronic acid |
| phAFP | Alpha fetoprotein plasmid DNA vaccine |
| PHENO | Phenobarbital |
| phGM-CSF HCC | Sargramostim plasmid DNA hepatocellular carcinoma vaccine adjuvant |
| PHP | Panhypopituitarism |
| PHR | Personal health record; Personal history; Personal medical history |
| PHTS | PTEN hamartoma tumor syndrome |
| PI | Principal investigator |
| PI3K | phosphatidylinositol-3 kinase; PI3 kinase |
| PI-88 | Heparanase inhibitor PI-88 |
| PICC | Peripherally inserted central catheter |
| PICN | Paclitaxel injection concentrate for nanodispersion |
| PID | Pelvic inflammatory disease |
| PIF-1 | Preimplantation factor PIF-1 |
| pIL-12 | interleukin-12 gene |
| PIN | Prostatic intraepithelial neoplasia |
| PIPE | Piperine extract (standardized) |
| PJS | Peutz-Jeghers syndrome |
| PKC | Protein kinase C |
| PKC412 | Midostaurin; N-benzoyl-staurosporine; Rydapt |
| PKU | Phenylketonuria |
| pLADD | Personalized live-attenuated double-deleted Listeria monocytogenes |
| PLCB | Placebo |
| PLCIS | Pleomorphic lobular carcinoma in situ |
| PLE | Polypodium leucotomos extract |
| PLK-1 inhibitor BI 6727 | Volasertib |
| PLK-1 inhibitor GSK-461364 | Polo-like kinase 1 inhibitor GSK-461364 |
| PLL | Prolymphocytic leukemia |
| PL-MLP | Pegylated liposomal mitomycin C lipid-based prodrug |
| PLX4032 | BRAF (V600E) kinase inhibitor RO5185426; Vemurafenib; Zelboraf |
| PMCV | Polyvalent melanoma vaccine |
| PMM | Pentamethylmelamine |
| PMN | Granular leukocyte; Granulocyte; Polymorphonuclear leukocyte |
| PMO AVI-4126 | Phosphorodiamidate morpholino oligomer AVI-4126 |
| PMPA | Tenofovir |
| PN401 | Triacetyluridine; Uridine triacetate; Vistogard |
| PNA | Purine nucleoside analog |
| PNET | Primitive neuroectodermal tumor |
| PNH | Paroxysmal nocturnal hemoglobinuria |
| PNU 155971 | Exemestane |
| PNU-93914 | Liposomal paclitaxel; LipoTaxen; Paclitaxel liposome |
| POH | Perillyl alcohol |
| poly-ICLC | Stabilized polyriboinosinic/polyribocytidylic acid; Polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose; Polyriboinosinic-polyribocytidylic acid-polylysine carboxymethylcellulose |
| PP | Pancreatic polypeptide |
| PPI | Proton pump inhibitor |
| PPI inhibitor AP611074 | HPV E1/E2 interaction inhibitor gel AP611074 |
| PPM | PLZ4-coated paclitaxel-loaded micelle formulation |
| PPN | Partial parenteral nutrition |
| pPNET | Ewing sarcoma; Peripheral primitive neuroectodermal tumor |
| PPS | Pentosan polysulfate sodium |
| PPV | Positive predictive value |
| PR | Progesterone receptor |
| PR1 vac | PR1 leukemia peptide vaccine |
| PRAV | Pravastatin sodium |
| PRCA | Pure red cell aplasia |
| PRCC | Papillary kidney cancer; Papillary renal cell carcinoma |
| PRDL | Prednisolone |
| PRED | Prednisone |
| PRES | Posterior reversible encephalopathy syndrome; Reversible posterior leukoencephalopathy syndrome |
| PRG | Therapeutic progesterone |
| PRO | Patient-reported outcome |
| PROB | Probenecid |
| ProGP | Progenipoietin |
| prohibitin-TP01 | Prohibitin-targeting peptide 1 |
| PRP | Platelet-rich plasma |
| PRRT | Peptide receptor radionuclide therapy |
| PRS | Polygenic risk score |
| PS-341 | Bortezomib; Velcade |
| PSA | Prostate-specific antigen |
| PSA PEP VAC | PSA:154-163(155L) peptide vaccine |
| PSK | polysaccharide-K |
| PSMA | Prostate-specific membrane antigen |
| PT-100 | Talabostat mesylate |
| PTC | Percutaneous transhepatic cholangiography |
| PTCD | Percutaneous transhepatic biliary drainage; Percutaneous transhepatic cholangiodrainage |
| PTEN | PTEN tyrosine phosphatase |
| PTH | Parathormone; Parathyrin; Parathyroid hormone |
| PTHrP (1-36) | Parathyroid hormone-related protein (1-36) |
| PTLD | Post-transplant lymphoproliferative disorder |
| PTS | Para-toluenesulfonamide |
| PTSD | Post-traumatic stress disorder |
| PTX | Pentoxifylline |
| PUFA | Polyunsaturated fatty acid |
| PV | Pharmacovigilance |
| PV-10 | Rose bengal disodium 10% |
| PVP iodine | Povidone-iodine solution |
| PXD101 | Beleodaq; Belinostat |
| PXM | Piroxicam |
| PYC | French maritime pine bark extract |
| PZA | Pyrazoloacridine |
| PZD | Piperazinedione |
| PZDH | Pyrazine diazohydroxide |